FinnAdvance announced closing a seed round of €550k led by Voima Ventures and Finnish angel investors Leena Niemistö and Sauli Törmälä.

FinnAdvance, on Oulu, Finland-based biotech startup, announced securing a seed investment round totalling €550k ($600k).

The funding was provided by investors from Finland, including institutional Voima Ventures and angels Leena Niemistö and Sauli Törmälä.

Finnadvance, founded at the end of 2018 and led by CEO Prateek Singh, manufactures multi-channel 3-D microfluidic organ-on-a-chips that simulate the activities, mechanics and physiological response of entire organs and organ systems. In short, the company simulates the human body’s physiology on a microfluidic device, where small tissue and organ fragments are grown for molecule and drug testing. The technology allows more human-like pre-clinical drug testing, fast repurposing of old drugs and in the long term development of personalized therapies and medicines.

Prior to this capital investment round, Finnadvance raised money from Icebreaker.